Novo Nordisk A/s

Novozymes A/s

Novozymes Adenium Biotech A/s

Novozymes Adenivro Biotech A/s

Novozymes Aderium Biotech A/s

Mogens Trier Hansen

Per Holse Mygind

Dorthe Sandvang

Allan Svendsen

Kim Borch

Shamkant Anant Patkar

Dorotea Raventos Segura

Ib Groth Clausen

Michi Egel-Mitani

Marianne Vind Soerensen

Kirk Matthew Schnorr

Torben Halkier

Leonardo De Maria

Sven Pedersen

Ole Kirk

Jan Lehmbeck

Kjeld Norris

Christian Isak Jorgensen

Jens J Brange

Masanobu Abo

Hans-Henrik Kristensen Hoegenhaug

Yukiko Takamura

Miyoko Hashida

Birthe Marie Ravn

Marianne Vind Sorensen

Hans-Henrik Hogenhaug Kristensen

Shamkant Anant Pathar

The present invention relates to a method of producing a protein of interest comprising: (a) cultivating a mutant cell under conditions conducive for production of the protein wherein the mutant has a reduced or no expression of an endogenous polypeptide shown in SEQ ID NO: 2 compared to a parent host cell grown under the same conditions; and optionally (b) recovering the protein of interest.

Method for increasing expression yield of a protein of interest

The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Polypeptides having antimicrobial activity and polynucleotides encoding same

The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.

[object Object]

The disclosure relates to a filamentous fungal cell in which an endogenous alkaline protease activity, an endogenous neutral metalloprotease activity, an endogenous serine protease activity, and an endogenous kexin maturase activity have been completely or partially inactivated. Particularly the endogenous alkaline protease activity, the endogenous.neutral metalloprotease activity, the endogenous serine protease activity, and the kexin maturase activity are encoded by the alp, npI, pepC and kexB genes respectively. The filamentous fungal cell is particularly suitable for production of heterologous proteins such as antibodies.

Use of fungal mutants for expression of antibodies

Polypeptides having antimicrobial activity and polynucleotides encoding the same

C. antarctica lipase variants

A DNA sequence encoding a lipase having the amino acid sequence shown in SEQ ID NO:2. The lipase has a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule and, located in a critical position of a lipid contact zone of the lipase structure, an amino acid residue different from an aromatic amino acid residue, which amino acid residue interacts with a lipid substrate at or during hydrolysis, in which lipase variant of the amino acid residue has been replaced by an aromatic amino acid residue so as to confer to the variant an increased specific activity as compared to that of the parent lipase.

C. antarctica lipase and lipase variants

Lipases from hyphozyma

Novel rapid-acting human insulin analogues are provided having less tendency to self-association into dimers, tetramers, hexamers, or polymers. The novel human insulin analogues are formed by substituting one or more of the amino acid residues of human insulin with naturally occuring amino acid residues. The amino acid residue substitutions are preferably more hydrophilic than the natural amino acid residue at the respective position in the molecule. Furthermore, the insulin analogues have the same charge or a greater negative charge at neutral pH than that of human insulin. Preferred amino acid substitutions are Asp, Glu, Ser, Thr, His, and Ile, and more preferred substitutions are Asp and Glu. The novel insulin analogues can be used for the preparation of rapid-acting insulin solutions.

Insulin analogues

Growing community of inventors

Lynge, Denmark

Mogens Trier Hansen